Panuveitis

Immune MONDO:0017255 Pathograph 24 Show in embeddings browser Uveitis Eye disorder

Panuveitis is an anatomic class of uveitis in which inflammation involves all uveal layers rather than remaining restricted to anterior, intermediate, or posterior compartments. It may be infectious, idiopathic, or associated with a systemic inflammatory disease, and is managed as a high-risk form of uveitis because uncontrolled inflammation can cause macular edema, retinal detachment, cataract, glaucoma, optic nerve damage, and permanent vision loss.

Ask OpenScientist

Ask a research question about Panuveitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part
IMMUNE RHEUMATOLOGIC INFECTIOUS DISEASES
👪

Inheritance

1
Sporadic or multifactorial susceptibility HP:0003745
Panuveitis generally arises sporadically or through multifactorial interactions between host immunogenetic susceptibility (including MHC/HLA alleles and immune-regulatory loci) and infectious or environmental triggers, with 27% to 51% of uveitis presentations remaining idiopathic despite workup.
Sporadic
Show evidence (2 references)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"In the US and Europe, 27% to 51% of uveitis cases are idiopathic, and 37% to 49% are associated with systemic disease, such as axial spondyloarthritis."
Adult uveitis review documenting that a large fraction of cases arise idiopathically or in association with multifactorial systemic inflammatory diseases rather than single-gene inheritance.
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"The interaction between genetic predisposition and environmental triggers is central to the onset of uveitis."
Review of uveitis immunopathogenesis confirming multifactorial onset driven by polygenic predisposition interacting with environmental or infectious triggers.
◆

Subtypes

2
Noninfectious panuveitis
Immune-mediated panuveitis arising either in association with systemic autoimmune or autoinflammatory disorders (such as sarcoidosis, Behcet disease, or Vogt-Koyanagi-Harada disease) or as idiopathic pan-uveal inflammation without an identifiable infectious pathogen; accounted for 87.1% of panuveitic eyes in the Hellenic Study of Uveitis.
Show evidence (2 references)
PMID:37428299 SUPPORT PRIMARY RESULT Human clinical
"Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
Large tertiary-center cohort study quantifying noninfectious panuveitis as the predominant etiologic subtype of panuveitis.
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries."
Adult uveitis review establishing the primary etiologic division into noninfectious and infectious forms.
Infectious panuveitis
Panuveitis caused by direct intraocular infection or pathogen-driven inflammation across all uveal layers (including toxoplasmosis, herpesviruses, tuberculosis, syphilis, and HIV-associated infections); accounted for 12.9% of panuveitic eyes in the Hellenic Study of Uveitis.
Show evidence (2 references)
PMID:37428299 SUPPORT PRIMARY RESULT Human clinical
"Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
Large tertiary-center cohort study quantifying the infectious subtype of panuveitis.
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries."
Adult uveitis review summarizing major infectious etiologies of uveitis and their geographic variation.
⚙

Pathophysiology

4
Pan-uveal intraocular inflammation
Panuveitis reflects inflammation throughout the uveal tract, including the iris, ciliary body, and choroid, with spillover to adjacent vitreous and retinal structures.
lymphocyte CL:0000542 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves lymphocyte (CL:0000542). CL:0000542 is a cell type from the Cell Ontology. macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
inflammatory response GO:0006954 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. immune response GO:0006955 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal immune response (GO:0006955). GO:0006955 is a biological process from the Gene Ontology.
Downstream
Leukocyte trafficking across ocular barriers Diffuse pan-uveal cytokine signaling and endothelial activation drive leukocyte recruitment across blood-ocular barriers into all compartments.
Panuveitis Inflammation spanning the iris, ciliary body, and choroid directly manifests clinically as panuveitis.
Blurred vision Diffuse intraocular inflammation disrupts ocular transparency and retinal function.
Photophobia Anterior-segment iris and ciliary body inflammation within panuveitis triggers light-evoked ciliary spasm and photophobia.
Ocular pain Inflammatory involvement of the iris and ciliary body within panuveitis causes ocular pain.
Floaters Spillover of inflammatory cells and exudates into the vitreous cavity causes vitreous opacities perceived as floaters.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"panuveitis involves all uveal layers (7%-32%)."
This review directly defines panuveitis as involvement of all uveal layers.
Leukocyte trafficking across ocular barriers
Active panuveitis includes leukocyte recruitment into immune-privileged eye compartments, with inflammatory cells and mediators entering the aqueous, vitreous, retina, and choroid.
lymphocyte CL:0000542 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves lymphocyte (CL:0000542). CL:0000542 is a cell type from the Cell Ontology. neutrophil CL:0000775 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neutrophil (CL:0000775). CL:0000775 is a cell type from the Cell Ontology.
leukocyte migration GO:0050900 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased leukocyte migration (GO:0050900). GO:0050900 is a biological process from the Gene Ontology. leukocyte chemotaxis GO:0030595 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased leukocyte chemotaxis (GO:0030595). GO:0030595 is a biological process from the Gene Ontology.
Downstream
Macular edema Cellular infiltration and inflammatory exudation across compromised blood-retinal barriers promote macular edema.
Retinal detachment Severe chorioretinal inflammation and subretinal exudation or vitreoretinal traction lead to serous or tractional retinal detachment.
Cataract Chronic intraocular compartment inflammation (along with corticosteroid exposure in treated patients) accelerates lens opacification.
Glaucoma Chronic intraocular inflammation (as well as corticosteroid-induced ocular hypertension in treated patients) impairs aqueous humor outflow and elevates intraocular pressure, causing uveitic glaucoma.
Optic nerve damage Posterior-segment inflammatory infiltration, papillitis, and elevated intraocular pressure contribute to optic nerve injury.
Show evidence (1 reference)
PMID:39157460 SUPPORT REVIEW SYNTHESIS Human clinical
"inflammation within various layers of the eye."
This noninfectious uveitis review supports multilayer ocular inflammation as the core disease process.
Infectious and systemic inflammatory triggers
Panuveitis can arise from infectious causes, idiopathic inflammation, or systemic immune-mediated disease. Etiologic classification is clinically central because antimicrobial therapy is required for infectious disease, whereas noninfectious disease often requires corticosteroids and steroid-sparing immunosuppression.
immune response GO:0006955 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal immune response (GO:0006955). GO:0006955 is a biological process from the Gene Ontology. inflammatory response GO:0006954 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology.
Downstream
Pan-uveal intraocular inflammation Infectious or systemic immune-mediated triggers initiate pan-uveal intraocular inflammation.
Show evidence (2 references)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Uveitis is classified as noninfectious or infectious"
This review supports infectious versus noninfectious classification as a major etiologic branch.
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"37% to 49% are associated with systemic disease"
This supports systemic inflammatory disease as an important associated cause of uveitis.
Immunogenetic susceptibility
Polymorphisms in MHC class I and II molecules (such as HLA-B*51 and HLA-B27) alter ocular peptide presentation to T lymphocytes, while susceptibility variants in the Th17-pathway receptor IL23R and haploinsufficiency of the NF-kappaB negative regulator TNFAIP3 (A20) dysregulate adaptive and innate immune signaling, lowering activation thresholds for intraocular autoimmunity.
HLA-B hgnc:4932 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HLA-B (hgnc:4932). hgnc:4932 is a gene from the HUGO Gene Nomenclature Committee. IL23R hgnc:19100 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves IL23R (hgnc:19100). hgnc:19100 is a gene from the HUGO Gene Nomenclature Committee. TNFAIP3 hgnc:11896 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves TNFAIP3 (hgnc:11896). hgnc:11896 is a gene from the HUGO Gene Nomenclature Committee.
antigen processing and presentation of peptide antigen via MHC class I GO:0002474 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal antigen processing and presentation of peptide antigen via MHC class I (GO:0002474). GO:0002474 is a biological process from the Gene Ontology. activation of immune response GO:0002253 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased activation of immune response (GO:0002253). GO:0002253 is a biological process from the Gene Ontology.
peptide antigen binding GO:0042605 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves abnormal peptide antigen binding (GO:0042605). GO:0042605 is a molecular function from the Gene Ontology. cytokine receptor activity GO:0004896 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves cytokine receptor activity (GO:0004896). GO:0004896 is a molecular function from the Gene Ontology. K63-linked deubiquitinase activity GO:0061578 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased K63-linked deubiquitinase activity (GO:0061578). GO:0061578 is a molecular function from the Gene Ontology.
Downstream
Pan-uveal intraocular inflammation Altered HLA ocular peptide presentation, Th17 pathway genetic susceptibility, and disinhibited NF-kappaB signaling lower activation thresholds and promote pan-uveal inflammation.
Show evidence (3 references)
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"As outlined above, HLA polymorphisms shape which ocular peptides are displayed to T-cells and modify risk; prominent examples include HLA-B27 with acute anterior uveitis, HLA-A29 with birdshot chorioretinopathy, and HLA-B*51 with Behçet’s disease (Table 2) (221)."
Review showing that HLA-B polymorphisms shape ocular peptide display to T cells and modify uveitis risk.
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"For example, IL23R is a key genetic component of Th17 signalling and is implicated in the pathophysiology of Behçet’s and Vogt-Koyanagi-Harada disease (223)."
Review implicating IL23R genetic susceptibility and Th17 signaling in Behcet and Vogt-Koyanagi-Harada panuveitis.
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"Additional immune-regulatory loci-STAT4, CCR1, IRF8, TNFAIP3 (A20)-have been linked in cohort- and disease-specific analyses. A20 haploinsufficiency, which normally acts as a brake on the NF-κB inflammation pathway, disinhibits NF-κB signalling, lowering activation thresholds for ocular..."
Review showing that TNFAIP3 (A20) haploinsufficiency removes negative feedback on NF-kappaB and lowers thresholds for ocular autoimmunity.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Panuveitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Eye 9
Panuveitis HP:0012121 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Panuveitis (HP:0012121). HP:0012121 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"panuveitis involves all uveal layers (7%-32%)."
This directly supports panuveitis as the anatomic inflammatory phenotype.
Photophobia HP:0000613 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Photophobia (HP:0000613). HP:0000613 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"eye redness, pain, photophobia, floaters, and blurred vision."
This review lists photophobia among common presenting symptoms of uveitis.
Blurred vision HP:0000622 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Blurred vision (HP:0000622). HP:0000622 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"eye redness, pain, photophobia, floaters, and blurred vision."
This review lists blurred vision among common presenting symptoms of uveitis.
Floaters Vitreous floaters HP:0100832 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Floaters, annotated with Vitreous floaters (HP:0100832). HP:0100832 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"eye redness, pain, photophobia, floaters, and blurred vision."
This review lists floaters among common presenting symptoms of uveitis.
Macular edema HP:0040049 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macular edema (HP:0040049). HP:0040049 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
This review lists macular edema among major complications of untreated uveitis.
Retinal detachment HP:0000541 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Retinal detachment (HP:0000541). HP:0000541 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
This review lists retinal detachment among major complications of untreated uveitis.
Cataract HP:0000518 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cataract (HP:0000518). HP:0000518 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
This review lists cataracts among major complications of untreated uveitis.
Glaucoma HP:0000501 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Glaucoma (HP:0000501). HP:0000501 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
This review lists glaucoma among major complications of untreated uveitis.
Optic nerve damage Abnormal optic nerve morphology HP:0000587 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic nerve damage, annotated with Abnormal optic nerve morphology (HP:0000587). HP:0000587 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
This review lists optic nerve damage among major complications of untreated uveitis.
Constitutional 1
Ocular pain HP:0200026 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ocular pain (HP:0200026). HP:0200026 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"eye redness, pain, photophobia, floaters, and blurred vision."
This review lists pain among common presenting symptoms of uveitis.
🧬

Genetic Associations

3
HLA-B (MHC class I risk alleles (including HLA-B*51 in Behcet-associated panuveitis and HLA-B27 in spondyloarthritis-associated uveitis))
Gene: HLA-B hgnc:4932 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HLA-B (hgnc:4932). hgnc:4932 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: RISK_FACTOR
Show evidence (2 references)
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"As outlined above, HLA polymorphisms shape which ocular peptides are displayed to T-cells and modify risk; prominent examples include HLA-B27 with acute anterior uveitis, HLA-A29 with birdshot chorioretinopathy, and HLA-B*51 with Behçet’s disease (Table 2) (221)."
Review detailing how HLA-B alleles (HLA-B*51 and HLA-B27) alter ocular peptide display and modify uveitis risk.
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Incidence and prevalence of uveitis are influenced by genetic factors (eg, human leukocyte antigen-B27), environmental factors (eg, air pollution), and infection rates."
Adult uveitis review highlighting HLA-B27 as a major genetic risk factor influencing uveitis occurrence.
IL23R (Th17 pathway susceptibility locus in Behcet disease and Vogt-Koyanagi-Harada panuveitis)
Gene: IL23R hgnc:19100 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is IL23R (hgnc:19100). hgnc:19100 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"For example, IL23R is a key genetic component of Th17 signalling and is implicated in the pathophysiology of Behçet’s and Vogt-Koyanagi-Harada disease (223)."
Review linking IL23R genetic susceptibility and Th17 signaling to major panuveitis-associated diseases.
TNFAIP3 (Immune-regulatory susceptibility locus and NF-kappaB negative regulator (A20) linked to ocular autoimmunity)
Gene: TNFAIP3 hgnc:11896 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TNFAIP3 (hgnc:11896). hgnc:11896 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"Additional immune-regulatory loci-STAT4, CCR1, IRF8, TNFAIP3 (A20)-have been linked in cohort- and disease-specific analyses. A20 haploinsufficiency, which normally acts as a brake on the NF-κB inflammation pathway, disinhibits NF-κB signalling, lowering activation thresholds for ocular..."
Review describing TNFAIP3 (A20) as an immune-regulatory locus whose loss of function disinhibits NF-kappaB signaling and promotes ocular autoimmunity.
💊

Medical Actions

7
Etiology-directed antimicrobial therapy
Action: antimicrobial pharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is antimicrobial pharmacotherapy, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Infectious panuveitis requires treatment of the causative pathogen before or alongside anti-inflammatory therapy.
Mechanism Target:
INHIBITS Infectious and systemic inflammatory triggers — Antimicrobial therapy targets infectious causes that can drive panuveitis.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Infectious uveitis requires systemic antimicrobial treatment."
This review directly supports organism-directed antimicrobial treatment for infectious uveitis.
Systemic corticosteroid therapy
Action: systemic corticosteroid therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is systemic corticosteroid therapy (NCIT:C122080). NCIT:C122080 is a clinical intervention from the NCI Thesaurus. Ontology label: Systemic Corticosteroid Therapy NCIT:C122080
Moderate to severe panuveitis often requires systemic corticosteroids to rapidly suppress sight-threatening intraocular inflammation across all uveal layers; long-term systemic or local corticosteroid exposure carries risks of cataract and elevated intraocular pressure/glaucoma, motivating transition to steroid-sparing therapy when chronic control is needed.
Mechanism Target:
INHIBITS Pan-uveal intraocular inflammation — Systemic corticosteroids suppress active intraocular inflammation across all uveal layers.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"require systemic and/or intravitreal corticosteroids and immunosuppressive agents."
This review directly supports systemic corticosteroids for high-risk panuveitis.
Intravitreal corticosteroid therapy
Action: intravitreal corticosteroid therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is intravitreal corticosteroid therapy, annotated with Localized Corticosteroid Therapy (NCIT:C121367). NCIT:C121367 is a clinical intervention from the NCI Thesaurus. Ontology label: Localized Corticosteroid Therapy NCIT:C121367
Agent: dexamethasone CHEBI:41879 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dexamethasone (CHEBI:41879). CHEBI:41879 is a therapeutic agent from Chemical Entities of Biological Interest. triamcinolone CHEBI:9667 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses triamcinolone (CHEBI:9667). CHEBI:9667 is a therapeutic agent from Chemical Entities of Biological Interest.
Intravitreal corticosteroid injections or sustained-release implants (such as dexamethasone or triamcinolone) provide targeted posterior-segment and pan-uveal anti-inflammatory control in moderate to severe noninfectious panuveitis, though local corticosteroid delivery carries elevated risks of cataract progression and corticosteroid-induced glaucoma.
Mechanism Target:
INHIBITS Pan-uveal intraocular inflammation — Intravitreal corticosteroids locally suppress posterior-segment and pan-uveal inflammation.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"require systemic and/or intravitreal corticosteroids and immunosuppressive agents."
This review directly supports intravitreal corticosteroids alongside systemic therapy for moderate to severe panuveitis.
Steroid-sparing immunosuppressive therapy
Action: immune suppressant agent therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immune suppressant agent therapy, annotated with Immunosuppressive Therapy (NCIT:C15261). NCIT:C15261 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunosuppressive Therapy NCIT:C15261
Chronic, recurrent, bilateral, or vision-threatening noninfectious panuveitis commonly requires steroid-sparing immunosuppression such as methotrexate or mycophenolate mofetil.
Mechanism Target:
INHIBITS Pan-uveal intraocular inflammation — Immunosuppressive therapy reduces recurrent noninfectious ocular inflammation while limiting corticosteroid exposure.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"require systemic and/or intravitreal corticosteroids and immunosuppressive agents."
This review directly supports immunosuppressive agents for moderate to severe panuveitis.
Methotrexate
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: methotrexate CHEBI:44185 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses methotrexate (CHEBI:44185). CHEBI:44185 is a therapeutic agent from Chemical Entities of Biological Interest.
Methotrexate is a disease-modifying antirheumatic drug used as a steroid-sparing treatment option for posterior-segment noninfectious uveitis that can include panuveitis.
Mechanism Target:
INHIBITS Pan-uveal intraocular inflammation — Methotrexate is used to suppress noninfectious ocular inflammation while reducing corticosteroid dependence.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"disease-modifying antirheumatic drugs such as methotrexate achieved remission of inflammation in 52.1% (95% CI, 38.6%-67.1%) of patients, and mycophenolate mofetil controlled inflammation in 70.9% (95% CI, 57.1%-83.5%)"
The review provides quantitative human clinical outcome data for methotrexate as a steroid-sparing DMARD in posterior-segment uveitis care.
Mycophenolate mofetil
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: mycophenolate mofetil CHEBI:8764 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses mycophenolate mofetil (CHEBI:8764). CHEBI:8764 is a therapeutic agent from Chemical Entities of Biological Interest.
Mycophenolate mofetil is a disease-modifying antirheumatic drug used as a steroid-sparing treatment option for posterior-segment noninfectious uveitis that can include panuveitis.
Mechanism Target:
INHIBITS Pan-uveal intraocular inflammation — Mycophenolate mofetil is used to suppress noninfectious ocular inflammation while reducing corticosteroid dependence.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"disease-modifying antirheumatic drugs such as methotrexate achieved remission of inflammation in 52.1% (95% CI, 38.6%-67.1%) of patients, and mycophenolate mofetil controlled inflammation in 70.9% (95% CI, 57.1%-83.5%)"
The review provides quantitative human clinical outcome data for mycophenolate mofetil as a steroid-sparing DMARD in posterior-segment uveitis care.
Adalimumab
Action: anti-TNF biologic therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is anti-TNF biologic therapy, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: Adalimumab NCIT:C65216 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses Adalimumab (NCIT:C65216). NCIT:C65216 is a therapeutic agent from the NCI Thesaurus.
Adalimumab is a steroid-sparing biologic option for active or inactive noninfectious intermediate, posterior, or panuveitic uveitis when inflammation is not adequately controlled with corticosteroid-based therapy.
Mechanism Target:
INHIBITS Pan-uveal intraocular inflammation — Anti-TNF treatment reduces noninfectious ocular inflammatory activity.
Show evidence (3 references)
PMID:27602665 SUPPORT PRIMARY RESULT Human clinical
"active noninfectious intermediate uveitis, posterior uveitis, or panuveitis"
VISUAL I enrolled the panuveitis-relevant noninfectious uveitis population.
PMID:27602665 SUPPORT PRIMARY RESULT Human clinical
"median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group"
VISUAL I supports adalimumab efficacy in active noninfectious intermediate, posterior, or panuveitis.
PMID:27542302 SUPPORT PRIMARY RESULT Human clinical
"Adalimumab significantly lowered the risk of uveitic flare or loss of visual acuity upon corticosteroid withdrawal"
VISUAL II supports adalimumab as maintenance therapy for inactive steroid-dependent noninfectious intermediate, posterior, or panuveitic uveitis.
🔬

Biochemical Markers

2
Tumor necrosis factor-alpha (TNF-alpha) (Elevated)
Context: Aqueous humor and serum in active uveitis
Show evidence (1 reference)
PMID:39157460 SUPPORT REVIEW SYNTHESIS Human clinical
"The pro-inflammatory cytokine TNF-α is believed to be a pivotal factor in uveitis inflammation, with upregulated levels in both aqueous humor and serum among uveitis patients."
Review documenting elevated aqueous humor and serum TNF-alpha levels in uveitis patients.
Interleukin-6 (IL-6) (Elevated)
Context: Intraocular fluids in active uveitis and uveitic macular edema
Show evidence (1 reference)
PMID:39157460 SUPPORT REVIEW SYNTHESIS Human clinical
"Elevated intraocular levels of IL-6 are observed in certain conditions like uveitis, central retinal vein occlusion and diabetes"
Review documenting elevated intraocular IL-6 concentrations in uveitis.
🔬

Diagnosis

2
Anatomic classification and etiologic workup
Diagnosis combines ophthalmic examination to establish the panuveitis anatomic pattern with directed evaluation for infectious and systemic inflammatory causes.
clinical assessment NCIT:C124351 NCI Thesaurus (NCIT)
Results: Inflammation involving all uveal layers supports the panuveitis anatomic classification; infectious and systemic causes should then be assessed.
Show evidence (1 reference)
PMID:36164924 SUPPORT REVIEW SYNTHESIS Human clinical
"The uveitides are a collection of over 30 diseases characterised by intraocular inflammation."
SUN provides the standardized uveitis classification framework used to define anatomic classes.
Fundus autofluorescence imaging
FAF can help document posterior and panuveitis-related retinal or choroidal abnormalities and monitor clinical course as part of multimodal imaging.
fundus autofluorescence imaging
Results: Retinal or choroidal autofluorescence abnormalities support posterior-segment inflammatory involvement.
Show evidence (1 reference)
PMID:38785922 SUPPORT REVIEW SYNTHESIS Human clinical
"FAF is of diagnostic value in detecting disease and following the clinical course."
This review supports FAF as a diagnostic and monitoring modality in posterior and panuveitis.
📈

Progression

1
ADULT
Age: 20-50 years
Uveitis, including panuveitis, predominantly presents in young and middle-aged working-age adults between 20 and 50 years of age.
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Uveitis predominantly affects individuals aged 20 to 50 years."
Adult uveitis review stating the predominant age of onset and presentation.
📊

Prevalence

2
General population (all uveitis, young and middle-aged adults aged 20-50 years predominating)
Annual incidence 17.0–52.0 per 100,000 person-years 1–9 per 10,000 per year
Overall uveitis has an annual incidence of 17 to 52 per 100,000 people (equivalent to 1.7 to 5.2 per 10,000 person-years), predominantly affecting young and middle-aged adults aged 20 to 50 years.
Show evidence (1 reference)
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"The annual incidence ranges from 17 to 52 per 100,000 people, with the condition predominantly affecting young and middle-aged adults aged 20 to 50 years (3)."
Review reporting the population-level annual incidence of uveitis (17 to 52 per 100,000 people).
Adult uveitis cohorts (panuveitis anatomical subtype share)
Unknown Unknown
Panuveitis accounts for 7% to 32% of all uveitis cases across clinical series. Measure type and prevalence class are set to UNKNOWN because this panuveitis-specific figure is an anatomical subtype share among uveitis cases rather than a population-denominator rate.
Show evidence (2 references)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
Review summarizing the proportion of adult uveitis cases classified anatomically as panuveitis (7%-32%).
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"Anterior uveitis represents the most common form, accounting for 41 to 60% of cases, followed by posterior uveitis at 17 to 23%, intermediate uveitis at 9 to 15%, and panuveitis at 7 to 32%."
Independent review corroborating the 7% to 32% anatomical subtype share of panuveitis among uveitis cases.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Panuveitis:

Intraocular lymphoma Not Yet Curated MONDO:0004351
Overlapping Features Neoplastic uveitic masquerade syndrome (most commonly primary vitreoretinal lymphoma) that presents with vitreous cellular infiltration and chorioretinal lesions mimicking chronic intermediate, posterior, or panuveitis.
Distinguishing Features
  • Neoplastic lymphoid infiltration rather than primary immune or infectious inflammation
  • Poor or transient response to corticosteroid monotherapy and requirement for diagnostic vitreous biopsy or cytology
Show evidence (1 reference)
PMID:41877771 SUPPORT REVIEW SYNTHESIS Human clinical
"Masquerade syndromes, accounting for 1 to 5% of presentations, comprise neoplastic processes and non-neoplastic entities such as ocular ischaemia."
Review identifying neoplastic masquerade syndromes as an important differential diagnostic category in patients presenting with uveitis.
Posterior uveitis
Overlapping Features Anatomic class of uveitis in which primary intraocular inflammation is restricted to the retina and/or choroid without predominant simultaneous involvement of the anterior chamber and vitreous cavity.
Distinguishing Features
  • Primary inflammation confined to the choroid and/or retina (17%-23% of uveitis cases) rather than involving all uveal layers simultaneously
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
Review distinguishing posterior uveitis (confined to choroid and/or retina) from panuveitis (involving all uveal layers).
Anterior uveitis
Overlapping Features Anatomic class of uveitis limited to the anterior segment (iris and ciliary body), representing the most common form of uveitis (41%-60% of cases).
Distinguishing Features
  • Inflammation restricted to the iris and ciliary body without chorioretinal or diffuse vitreous involvement
Show evidence (1 reference)
PMID:40434762 SUPPORT REVIEW SYNTHESIS Human clinical
"Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
Review distinguishing anterior uveitis (iris and ciliary body) from panuveitis (all uveal layers).
{ }

Source YAML

click to show 
name: Panuveitis
creation_date: '2026-05-09T15:13:56Z'
updated_date: '2026-10-16T22:55:00Z'
description: >-
  Panuveitis is an anatomic class of uveitis in which inflammation involves all
  uveal layers rather than remaining restricted to anterior, intermediate, or
  posterior compartments. It may be infectious, idiopathic, or associated with a
  systemic inflammatory disease, and is managed as a high-risk form of uveitis
  because uncontrolled inflammation can cause macular edema, retinal detachment,
  cataract, glaucoma, optic nerve damage, and permanent vision loss.
category: Immune
disease_term:
  preferred_term: panuveitis
  term:
    id: MONDO:0017255
    label: panuveitis
parents:
- Uveitis
- Eye disorder
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:37428299
      reference_title: "The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: "Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
      explanation: >-
        Large tertiary uveitis cohort demonstrating that 87.1% of panuveitic eyes
        are non-infectious immune-mediated uveitis.
    - reference: PMID:41877771
      reference_title: "The Immunopathogenesis of uveitis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Non-infectious aetiologies constitute 52 to 79% of cases. Conditions with established systemic associations include sarcoidosis (a multisystem granulomatous disorder), Behçet’s disease (a systemic vasculitis characterised by recurrent oral and genital ulceration), Vogt-Koyanagi-Harada syndrome (a multisystem autoimmune disorder targeting melanocytes), juvenile idiopathic arthritis, tubulointerstitial nephritis with uveitis syndrome, and multiple sclerosis."
      explanation: >-
        Immunopathogenesis review linking non-infectious uveitis to systemic
        autoimmune and granulomatous conditions including sarcoidosis, Behcet
        disease, and Vogt-Koyanagi-Harada syndrome.
  - classification_value: INFECTIOUS_DISEASES
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries."
      explanation: >-
        Adult uveitis review confirming infectious etiologies (toxoplasmosis,
        herpesviruses, tuberculosis, and HIV) as a major etiologic axis of uveitis
        and panuveitis.
inheritance:
- name: Sporadic or multifactorial susceptibility
  inheritance_term:
    preferred_term: Sporadic
    term:
      id: HP:0003745
      label: Sporadic
  description: >-
    Panuveitis generally arises sporadically or through multifactorial interactions
    between host immunogenetic susceptibility (including MHC/HLA alleles and
    immune-regulatory loci) and infectious or environmental triggers, with 27% to
    51% of uveitis presentations remaining idiopathic despite workup.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "In the US and Europe, 27% to 51% of uveitis cases are idiopathic, and 37% to 49% are associated with systemic disease, such as axial spondyloarthritis."
    explanation: >-
      Adult uveitis review documenting that a large fraction of cases arise
      idiopathically or in association with multifactorial systemic inflammatory
      diseases rather than single-gene inheritance.
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The interaction between genetic predisposition and environmental triggers is central to the onset of uveitis."
    explanation: >-
      Review of uveitis immunopathogenesis confirming multifactorial onset driven
      by polygenic predisposition interacting with environmental or infectious
      triggers.
has_subtypes:
- name: Noninfectious panuveitis
  description: >-
    Immune-mediated panuveitis arising either in association with systemic
    autoimmune or autoinflammatory disorders (such as sarcoidosis, Behcet
    disease, or Vogt-Koyanagi-Harada disease) or as idiopathic pan-uveal
    inflammation without an identifiable infectious pathogen; accounted for
    87.1% of panuveitic eyes in the Hellenic Study of Uveitis.
  evidence:
  - reference: PMID:37428299
    reference_title: "The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
    explanation: >-
      Large tertiary-center cohort study quantifying noninfectious panuveitis as
      the predominant etiologic subtype of panuveitis.
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries."
    explanation: >-
      Adult uveitis review establishing the primary etiologic division into
      noninfectious and infectious forms.
- name: Infectious panuveitis
  description: >-
    Panuveitis caused by direct intraocular infection or pathogen-driven
    inflammation across all uveal layers (including toxoplasmosis, herpesviruses,
    tuberculosis, syphilis, and HIV-associated infections); accounted for 12.9%
    of panuveitic eyes in the Hellenic Study of Uveitis.
  evidence:
  - reference: PMID:37428299
    reference_title: "The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
    explanation: >-
      Large tertiary-center cohort study quantifying the infectious subtype of
      panuveitis.
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries."
    explanation: >-
      Adult uveitis review summarizing major infectious etiologies of uveitis and
      their geographic variation.
prevalence:
- population: General population (all uveitis, young and middle-aged adults aged 20-50 years predominating)
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 17.0
  rate_high: 52.0
  rate_denominator: PERSON_YEARS
  notes: >-
    Overall uveitis has an annual incidence of 17 to 52 per 100,000 people
    (equivalent to 1.7 to 5.2 per 10,000 person-years), predominantly affecting
    young and middle-aged adults aged 20 to 50 years.
  evidence:
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The annual incidence ranges from 17 to 52 per 100,000 people, with the condition predominantly affecting young and middle-aged adults aged 20 to 50 years (3)."
    explanation: >-
      Review reporting the population-level annual incidence of uveitis (17 to 52
      per 100,000 people).
- population: Adult uveitis cohorts (panuveitis anatomical subtype share)
  measure_type: UNKNOWN
  prevalence_class: UNKNOWN
  notes: >-
    Panuveitis accounts for 7% to 32% of all uveitis cases across clinical
    series. Measure type and prevalence class are set to UNKNOWN because this
    panuveitis-specific figure is an anatomical subtype share among uveitis cases
    rather than a population-denominator rate.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
    explanation: >-
      Review summarizing the proportion of adult uveitis cases classified
      anatomically as panuveitis (7%-32%).
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Anterior uveitis represents the most common form, accounting for 41 to 60% of cases, followed by posterior uveitis at 17 to 23%, intermediate uveitis at 9 to 15%, and panuveitis at 7 to 32%."
    explanation: >-
      Independent review corroborating the 7% to 32% anatomical subtype share of
      panuveitis among uveitis cases.
progression:
- phase: ADULT
  age_range: 20-50 years
  notes: >-
    Uveitis, including panuveitis, predominantly presents in young and
    middle-aged working-age adults between 20 and 50 years of age.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Uveitis predominantly affects individuals aged 20 to 50 years."
    explanation: >-
      Adult uveitis review stating the predominant age of onset and presentation.
pathophysiology:
- name: Pan-uveal intraocular inflammation
  description: >-
    Panuveitis reflects inflammation throughout the uveal tract, including the
    iris, ciliary body, and choroid, with spillover to adjacent vitreous and
    retinal structures.
  cell_types:
  - preferred_term: lymphocyte
    term:
      id: CL:0000542
      label: lymphocyte
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: immune response
    modifier: ABNORMAL
    term:
      id: GO:0006955
      label: immune response
  downstream:
  - target: Leukocyte trafficking across ocular barriers
    description: Diffuse pan-uveal cytokine signaling and endothelial activation drive leukocyte recruitment across blood-ocular barriers into all compartments.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41877771
      reference_title: "The Immunopathogenesis of uveitis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Within the eye, effector T-cells are restimulated by resident microglia and recruited macrophages, driving cytokine cascades that disrupt the blood-retina barrier and amplify leukocyte recruitment."
      explanation: Review of uveitis immunopathogenesis linking intraocular cytokine cascades to blood-ocular barrier disruption and leukocyte recruitment.
  - target: Panuveitis
    description: Inflammation spanning the iris, ciliary body, and choroid directly manifests clinically as panuveitis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "panuveitis involves all uveal layers (7%-32%)."
      explanation: Review defining the clinical phenotype of panuveitis as inflammation across all uveal layers.
  - target: Blurred vision
    description: Diffuse intraocular inflammation disrupts ocular transparency and retinal function.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Uveitis is characterized by inflammation of the uvea-the middle portion of the eye composed of the iris, ciliary body, and choroid-causing eye redness, pain, photophobia, floaters, and blurred vision."
      explanation: Review linking intraocular uveal inflammation to blurred vision.
  - target: Photophobia
    description: Anterior-segment iris and ciliary body inflammation within panuveitis triggers light-evoked ciliary spasm and photophobia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Uveitis is characterized by inflammation of the uvea-the middle portion of the eye composed of the iris, ciliary body, and choroid-causing eye redness, pain, photophobia, floaters, and blurred vision."
      explanation: Review linking uveal inflammation to photophobia.
  - target: Ocular pain
    description: Inflammatory involvement of the iris and ciliary body within panuveitis causes ocular pain.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Uveitis is characterized by inflammation of the uvea-the middle portion of the eye composed of the iris, ciliary body, and choroid-causing eye redness, pain, photophobia, floaters, and blurred vision."
      explanation: Review linking uveal inflammation to ocular pain.
  - target: Floaters
    description: Spillover of inflammatory cells and exudates into the vitreous cavity causes vitreous opacities perceived as floaters.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Uveitis is characterized by inflammation of the uvea-the middle portion of the eye composed of the iris, ciliary body, and choroid-causing eye redness, pain, photophobia, floaters, and blurred vision."
      explanation: Review linking uveal inflammation to vitreous floaters.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "panuveitis involves all uveal layers (7%-32%)."
    explanation: This review directly defines panuveitis as involvement of all uveal layers.
- name: Leukocyte trafficking across ocular barriers
  description: >-
    Active panuveitis includes leukocyte recruitment into immune-privileged eye
    compartments, with inflammatory cells and mediators entering the aqueous,
    vitreous, retina, and choroid.
  cell_types:
  - preferred_term: lymphocyte
    term:
      id: CL:0000542
      label: lymphocyte
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: leukocyte migration
    modifier: INCREASED
    term:
      id: GO:0050900
      label: leukocyte migration
  - preferred_term: leukocyte chemotaxis
    modifier: INCREASED
    term:
      id: GO:0030595
      label: leukocyte chemotaxis
  downstream:
  - target: Macular edema
    description: Cellular infiltration and inflammatory exudation across compromised blood-retinal barriers promote macular edema.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: "Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
      explanation: Review documenting macular edema as a structural complication of untreated uveitic inflammation.
  - target: Retinal detachment
    description: Severe chorioretinal inflammation and subretinal exudation or vitreoretinal traction lead to serous or tractional retinal detachment.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: "Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
      explanation: Review documenting retinal detachment as a structural complication of untreated uveitis.
  - target: Cataract
    description: Chronic intraocular compartment inflammation (along with corticosteroid exposure in treated patients) accelerates lens opacification.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: "Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
      explanation: Review documenting cataract formation as a complication of untreated uveitis.
  - target: Glaucoma
    description: Chronic intraocular inflammation (as well as corticosteroid-induced ocular hypertension in treated patients) impairs aqueous humor outflow and elevates intraocular pressure, causing uveitic glaucoma.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: "Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
      explanation: Review documenting glaucoma as a structural complication of untreated uveitis.
  - target: Optic nerve damage
    description: Posterior-segment inflammatory infiltration, papillitis, and elevated intraocular pressure contribute to optic nerve injury.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: "Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
      explanation: Review documenting optic nerve damage as a complication of untreated uveitis.
  evidence:
  - reference: PMID:39157460
    reference_title: "Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "inflammation within various layers of the eye."
    explanation: This noninfectious uveitis review supports multilayer ocular inflammation as the core disease process.
- name: Infectious and systemic inflammatory triggers
  description: >-
    Panuveitis can arise from infectious causes, idiopathic inflammation, or
    systemic immune-mediated disease. Etiologic classification is clinically
    central because antimicrobial therapy is required for infectious disease,
    whereas noninfectious disease often requires corticosteroids and
    steroid-sparing immunosuppression.
  biological_processes:
  - preferred_term: immune response
    modifier: ABNORMAL
    term:
      id: GO:0006955
      label: immune response
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Pan-uveal intraocular inflammation
    description: Infectious or systemic immune-mediated triggers initiate pan-uveal intraocular inflammation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Uveitis is classified as noninfectious or infectious, with toxoplasmosis, herpes, tuberculosis, and HIV comprising 11% to 21% of infectious cases in high-income countries and 50% in low- and middle-income countries."
      explanation: Adult uveitis review documenting infectious pathogens (toxoplasmosis, herpesviruses, tuberculosis, and HIV) as direct triggers of intraocular uveitic inflammation.
    - reference: PMID:40434762
      reference_title: "Uveitis in Adults: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "In the US and Europe, 27% to 51% of uveitis cases are idiopathic, and 37% to 49% are associated with systemic disease, such as axial spondyloarthritis."
      explanation: Adult uveitis review linking systemic inflammatory diseases and idiopathic immune triggers to uveitis onset.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Uveitis is classified as noninfectious or infectious"
    explanation: This review supports infectious versus noninfectious classification as a major etiologic branch.
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "37% to 49% are associated with systemic disease"
    explanation: This supports systemic inflammatory disease as an important associated cause of uveitis.
- name: Immunogenetic susceptibility
  description: >-
    Polymorphisms in MHC class I and II molecules (such as HLA-B*51 and
    HLA-B27) alter ocular peptide presentation to T lymphocytes, while
    susceptibility variants in the Th17-pathway receptor IL23R and
    haploinsufficiency of the NF-kappaB negative regulator TNFAIP3 (A20)
    dysregulate adaptive and innate immune signaling, lowering activation
    thresholds for intraocular autoimmunity.
  genes:
  - preferred_term: HLA-B
    term:
      id: hgnc:4932
      label: HLA-B
  - preferred_term: IL23R
    term:
      id: hgnc:19100
      label: IL23R
  - preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  molecular_functions:
  - preferred_term: peptide antigen binding
    modifier: ABNORMAL
    term:
      id: GO:0042605
      label: peptide antigen binding
  - preferred_term: cytokine receptor activity
    term:
      id: GO:0004896
      label: cytokine receptor activity
  - preferred_term: K63-linked deubiquitinase activity
    modifier: DECREASED
    term:
      id: GO:0061578
      label: K63-linked deubiquitinase activity
  biological_processes:
  - preferred_term: antigen processing and presentation of peptide antigen via MHC class I
    modifier: ABNORMAL
    term:
      id: GO:0002474
      label: antigen processing and presentation of peptide antigen via MHC class I
  - preferred_term: activation of immune response
    modifier: INCREASED
    term:
      id: GO:0002253
      label: activation of immune response
  downstream:
  - target: Pan-uveal intraocular inflammation
    description: Altered HLA ocular peptide presentation, Th17 pathway genetic susceptibility, and disinhibited NF-kappaB signaling lower activation thresholds and promote pan-uveal inflammation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:41877771
      reference_title: "The Immunopathogenesis of uveitis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: "Additional immune-regulatory loci-STAT4, CCR1, IRF8, TNFAIP3 (A20)-have been linked in cohort- and disease-specific analyses. A20 haploinsufficiency, which normally acts as a brake on the NF-κB inflammation pathway, disinhibits NF-κB signalling, lowering activation thresholds for ocular autoimmunity (221, 224)."
      explanation: Review demonstrating that immunogenetic regulatory variants disinhibit NF-kappaB signaling and lower activation thresholds for ocular autoimmune inflammation.
  evidence:
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "As outlined above, HLA polymorphisms shape which ocular peptides are displayed to T-cells and modify risk; prominent examples include HLA-B27 with acute anterior uveitis, HLA-A29 with birdshot chorioretinopathy, and HLA-B*51 with Behçet’s disease (Table 2) (221)."
    explanation: Review showing that HLA-B polymorphisms shape ocular peptide display to T cells and modify uveitis risk.
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "For example, IL23R is a key genetic component of Th17 signalling and is implicated in the pathophysiology of Behçet’s and Vogt-Koyanagi-Harada disease (223)."
    explanation: Review implicating IL23R genetic susceptibility and Th17 signaling in Behcet and Vogt-Koyanagi-Harada panuveitis.
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Additional immune-regulatory loci-STAT4, CCR1, IRF8, TNFAIP3 (A20)-have been linked in cohort- and disease-specific analyses. A20 haploinsufficiency, which normally acts as a brake on the NF-κB inflammation pathway, disinhibits NF-κB signalling, lowering activation thresholds for ocular autoimmunity (221, 224)."
    explanation: Review showing that TNFAIP3 (A20) haploinsufficiency removes negative feedback on NF-kappaB and lowers thresholds for ocular autoimmunity.
phenotypes:
- category: Ophthalmologic
  name: Panuveitis
  description: Inflammation involves anterior, intermediate, and posterior eye compartments.
  phenotype_term:
    preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "panuveitis involves all uveal layers (7%-32%)."
    explanation: This directly supports panuveitis as the anatomic inflammatory phenotype.
- category: Ophthalmologic
  name: Photophobia
  description: Light sensitivity can occur during active anterior segment inflammation.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "eye redness, pain, photophobia, floaters, and blurred vision."
    explanation: This review lists photophobia among common presenting symptoms of uveitis.
- category: Ophthalmologic
  name: Blurred vision
  description: Vitreous haze, macular edema, or posterior segment inflammation can reduce visual clarity.
  phenotype_term:
    preferred_term: Blurred vision
    term:
      id: HP:0000622
      label: Blurred vision
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "eye redness, pain, photophobia, floaters, and blurred vision."
    explanation: This review lists blurred vision among common presenting symptoms of uveitis.
- category: Ophthalmologic
  name: Ocular pain
  description: Eye pain may accompany active intraocular inflammation.
  phenotype_term:
    preferred_term: Ocular pain
    term:
      id: HP:0200026
      label: Ocular pain
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "eye redness, pain, photophobia, floaters, and blurred vision."
    explanation: This review lists pain among common presenting symptoms of uveitis.
- category: Ophthalmologic
  name: Floaters
  description: Vitreous floaters can occur during active intraocular inflammation.
  phenotype_term:
    preferred_term: Floaters
    term:
      id: HP:0100832
      label: Vitreous floaters
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "eye redness, pain, photophobia, floaters, and blurred vision."
    explanation: This review lists floaters among common presenting symptoms of uveitis.
- category: Ophthalmologic
  name: Macular edema
  description: Macular edema is a sight-threatening inflammatory complication of uveitis and panuveitis.
  phenotype_term:
    preferred_term: Macular edema
    term:
      id: HP:0040049
      label: Macular edema
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
    explanation: This review lists macular edema among major complications of untreated uveitis.
- category: Ophthalmologic
  name: Retinal detachment
  description: Retinal detachment can occur as a severe structural complication of uncontrolled uveitis.
  phenotype_term:
    preferred_term: Retinal detachment
    term:
      id: HP:0000541
      label: Retinal detachment
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
    explanation: This review lists retinal detachment among major complications of untreated uveitis.
- category: Ophthalmologic
  name: Cataract
  description: Cataract is a common vision-threatening complication of untreated intraocular inflammation and is also promoted by local or systemic corticosteroid therapy.
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
    explanation: This review lists cataracts among major complications of untreated uveitis.
- category: Ophthalmologic
  name: Glaucoma
  description: Glaucoma can complicate panuveitis both through unchecked intraocular inflammation (trabeculitis and synechiae) and through corticosteroid-induced intraocular pressure elevation.
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
    explanation: This review lists glaucoma among major complications of untreated uveitis.
- category: Ophthalmologic
  name: Optic nerve damage
  description: Optic nerve injury is a sight-threatening complication of uncontrolled uveitis.
  phenotype_term:
    preferred_term: Optic nerve damage
    term:
      id: HP:0000587
      label: Abnormal optic nerve morphology
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
    explanation: This review lists optic nerve damage among major complications of untreated uveitis.
diagnosis:
- name: Anatomic classification and etiologic workup
  description: >-
    Diagnosis combines ophthalmic examination to establish the panuveitis
    anatomic pattern with directed evaluation for infectious and systemic
    inflammatory causes.
  diagnosis_term:
    preferred_term: clinical assessment
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  results: >-
    Inflammation involving all uveal layers supports the panuveitis anatomic
    classification; infectious and systemic causes should then be assessed.
  evidence:
  - reference: PMID:36164924
    reference_title: "The standardisation of uveitis nomenclature (SUN) project."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The uveitides are a collection of over 30 diseases characterised by intraocular inflammation."
    explanation: SUN provides the standardized uveitis classification framework used to define anatomic classes.
- name: Fundus autofluorescence imaging
  description: >-
    FAF can help document posterior and panuveitis-related retinal or choroidal
    abnormalities and monitor clinical course as part of multimodal imaging.
  diagnosis_term:
    preferred_term: fundus autofluorescence imaging
  results: Retinal or choroidal autofluorescence abnormalities support posterior-segment inflammatory involvement.
  evidence:
  - reference: PMID:38785922
    reference_title: "Fundus Autofluorescence in Posterior and Panuveitis-An Under-Estimated Imaging Technique: A Review and Case Series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "FAF is of diagnostic value in detecting disease and following the clinical course."
    explanation: This review supports FAF as a diagnostic and monitoring modality in posterior and panuveitis.
treatments:
- name: Etiology-directed antimicrobial therapy
  description: >-
    Infectious panuveitis requires treatment of the causative pathogen before or
    alongside anti-inflammatory therapy.
  treatment_term:
    preferred_term: antimicrobial pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Infectious and systemic inflammatory triggers
    treatment_effect: INHIBITS
    description: Antimicrobial therapy targets infectious causes that can drive panuveitis.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Infectious uveitis requires systemic antimicrobial treatment."
    explanation: This review directly supports organism-directed antimicrobial treatment for infectious uveitis.
- name: Systemic corticosteroid therapy
  description: >-
    Moderate to severe panuveitis often requires systemic corticosteroids to
    rapidly suppress sight-threatening intraocular inflammation across all uveal
    layers; long-term systemic or local corticosteroid exposure carries risks of
    cataract and elevated intraocular pressure/glaucoma, motivating transition
    to steroid-sparing therapy when chronic control is needed.
  treatment_term:
    preferred_term: systemic corticosteroid therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
  target_mechanisms:
  - target: Pan-uveal intraocular inflammation
    treatment_effect: INHIBITS
    description: Systemic corticosteroids suppress active intraocular inflammation across all uveal layers.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "require systemic and/or intravitreal corticosteroids and immunosuppressive agents."
    explanation: This review directly supports systemic corticosteroids for high-risk panuveitis.
- name: Intravitreal corticosteroid therapy
  description: >-
    Intravitreal corticosteroid injections or sustained-release implants (such
    as dexamethasone or triamcinolone) provide targeted posterior-segment and
    pan-uveal anti-inflammatory control in moderate to severe noninfectious
    panuveitis, though local corticosteroid delivery carries elevated risks of
    cataract progression and corticosteroid-induced glaucoma.
  treatment_term:
    preferred_term: intravitreal corticosteroid therapy
    term:
      id: NCIT:C121367
      label: Localized Corticosteroid Therapy
    therapeutic_agent:
    - preferred_term: dexamethasone
      term:
        id: CHEBI:41879
        label: dexamethasone
    - preferred_term: triamcinolone
      term:
        id: CHEBI:9667
        label: triamcinolone
  target_mechanisms:
  - target: Pan-uveal intraocular inflammation
    treatment_effect: INHIBITS
    description: Intravitreal corticosteroids locally suppress posterior-segment and pan-uveal inflammation.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "require systemic and/or intravitreal corticosteroids and immunosuppressive agents."
    explanation: This review directly supports intravitreal corticosteroids alongside systemic therapy for moderate to severe panuveitis.
- name: Steroid-sparing immunosuppressive therapy
  description: >-
    Chronic, recurrent, bilateral, or vision-threatening noninfectious
    panuveitis commonly requires steroid-sparing immunosuppression such as
    methotrexate or mycophenolate mofetil.
  treatment_term:
    preferred_term: immune suppressant agent therapy
    term:
      id: NCIT:C15261
      label: Immunosuppressive Therapy
  target_mechanisms:
  - target: Pan-uveal intraocular inflammation
    treatment_effect: INHIBITS
    description: Immunosuppressive therapy reduces recurrent noninfectious ocular inflammation while limiting corticosteroid exposure.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "require systemic and/or intravitreal corticosteroids and immunosuppressive agents."
    explanation: This review directly supports immunosuppressive agents for moderate to severe panuveitis.
- name: Methotrexate
  description: >-
    Methotrexate is a disease-modifying antirheumatic drug used as a
    steroid-sparing treatment option for posterior-segment noninfectious uveitis
    that can include panuveitis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
  target_mechanisms:
  - target: Pan-uveal intraocular inflammation
    treatment_effect: INHIBITS
    description: Methotrexate is used to suppress noninfectious ocular inflammation while reducing corticosteroid dependence.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "disease-modifying antirheumatic drugs such as methotrexate achieved remission of inflammation in 52.1% (95% CI, 38.6%-67.1%) of patients, and mycophenolate mofetil controlled inflammation in 70.9% (95% CI, 57.1%-83.5%)"
    explanation: The review provides quantitative human clinical outcome data for methotrexate as a steroid-sparing DMARD in posterior-segment uveitis care.
- name: Mycophenolate mofetil
  description: >-
    Mycophenolate mofetil is a disease-modifying antirheumatic drug used as a
    steroid-sparing treatment option for posterior-segment noninfectious uveitis
    that can include panuveitis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mycophenolate mofetil
      term:
        id: CHEBI:8764
        label: mycophenolate mofetil
  target_mechanisms:
  - target: Pan-uveal intraocular inflammation
    treatment_effect: INHIBITS
    description: Mycophenolate mofetil is used to suppress noninfectious ocular inflammation while reducing corticosteroid dependence.
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "disease-modifying antirheumatic drugs such as methotrexate achieved remission of inflammation in 52.1% (95% CI, 38.6%-67.1%) of patients, and mycophenolate mofetil controlled inflammation in 70.9% (95% CI, 57.1%-83.5%)"
    explanation: The review provides quantitative human clinical outcome data for mycophenolate mofetil as a steroid-sparing DMARD in posterior-segment uveitis care.
- name: Adalimumab
  description: >-
    Adalimumab is a steroid-sparing biologic option for active or inactive
    noninfectious intermediate, posterior, or panuveitic uveitis when
    inflammation is not adequately controlled with corticosteroid-based therapy.
  treatment_term:
    preferred_term: anti-TNF biologic therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Adalimumab
      term:
        id: NCIT:C65216
        label: Adalimumab
  target_mechanisms:
  - target: Pan-uveal intraocular inflammation
    treatment_effect: INHIBITS
    description: Anti-TNF treatment reduces noninfectious ocular inflammatory activity.
  evidence:
  - reference: PMID:27602665
    reference_title: "Adalimumab in Patients with Active Noninfectious Uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "active noninfectious intermediate uveitis, posterior uveitis, or panuveitis"
    explanation: VISUAL I enrolled the panuveitis-relevant noninfectious uveitis population.
  - reference: PMID:27602665
    reference_title: "Adalimumab in Patients with Active Noninfectious Uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group"
    explanation: VISUAL I supports adalimumab efficacy in active noninfectious intermediate, posterior, or panuveitis.
  - reference: PMID:27542302
    reference_title: "Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: "Adalimumab significantly lowered the risk of uveitic flare or loss of visual acuity upon corticosteroid withdrawal"
    explanation: VISUAL II supports adalimumab as maintenance therapy for inactive steroid-dependent noninfectious intermediate, posterior, or panuveitic uveitis.
biochemical:
- name: Tumor necrosis factor-alpha (TNF-alpha)
  presence: Elevated
  context: Aqueous humor and serum in active uveitis
  notes: >-
    Pro-inflammatory cytokine upregulated in both aqueous humor and serum of
    uveitis patients, serving as a central mediator of intraocular inflammation
    and the molecular target of anti-TNF-alpha biologics such as adalimumab.
  evidence:
  - reference: PMID:39157460
    reference_title: "Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "The pro-inflammatory cytokine TNF-α is believed to be a pivotal factor in uveitis inflammation, with upregulated levels in both aqueous humor and serum among uveitis patients."
    explanation: >-
      Review documenting elevated aqueous humor and serum TNF-alpha levels in
      uveitis patients.
- name: Interleukin-6 (IL-6)
  presence: Elevated
  context: Intraocular fluids in active uveitis and uveitic macular edema
  notes: >-
    Pro-inflammatory cytokine elevated inside the eye during active uveitis that
    promotes Th17 differentiation, vascular endothelial growth factor expression,
    and blood-retinal barrier breakdown leading to macular edema.
  evidence:
  - reference: PMID:39157460
    reference_title: "Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Elevated intraocular levels of IL-6 are observed in certain conditions like uveitis, central retinal vein occlusion and diabetes"
    explanation: >-
      Review documenting elevated intraocular IL-6 concentrations in uveitis.
genetic:
- name: HLA-B
  gene_term:
    preferred_term: HLA-B
    term:
      id: hgnc:4932
      label: HLA-B
  relationship_type: RISK_FACTOR
  association: MHC class I risk alleles (including HLA-B*51 in Behcet-associated panuveitis and HLA-B27 in spondyloarthritis-associated uveitis)
  notes: >-
    Polymorphisms in HLA-B shape ocular peptide presentation to T cells and
    modify uveitis susceptibility across anatomical and syndromic subtypes,
    including HLA-B*51 in Behcet disease and HLA-B27 in acute anterior and
    spondyloarthritis-associated uveitis.
  evidence:
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "As outlined above, HLA polymorphisms shape which ocular peptides are displayed to T-cells and modify risk; prominent examples include HLA-B27 with acute anterior uveitis, HLA-A29 with birdshot chorioretinopathy, and HLA-B*51 with Behçet’s disease (Table 2) (221)."
    explanation: >-
      Review detailing how HLA-B alleles (HLA-B*51 and HLA-B27) alter ocular
      peptide display and modify uveitis risk.
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Incidence and prevalence of uveitis are influenced by genetic factors (eg, human leukocyte antigen-B27), environmental factors (eg, air pollution), and infection rates."
    explanation: >-
      Adult uveitis review highlighting HLA-B27 as a major genetic risk factor
      influencing uveitis occurrence.
- name: IL23R
  gene_term:
    preferred_term: IL23R
    term:
      id: hgnc:19100
      label: IL23R
  relationship_type: SUSCEPTIBILITY
  association: Th17 pathway susceptibility locus in Behcet disease and Vogt-Koyanagi-Harada panuveitis
  notes: >-
    Encodes the interleukin-23 receptor subunit that stabilizes pathogenic Th17
    effector responses implicated in classic panuveitic syndromes including
    Behcet disease and Vogt-Koyanagi-Harada disease.
  evidence:
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "For example, IL23R is a key genetic component of Th17 signalling and is implicated in the pathophysiology of Behçet’s and Vogt-Koyanagi-Harada disease (223)."
    explanation: >-
      Review linking IL23R genetic susceptibility and Th17 signaling to major
      panuveitis-associated diseases.
- name: TNFAIP3
  gene_term:
    preferred_term: TNFAIP3
    term:
      id: hgnc:11896
      label: TNFAIP3
  relationship_type: SUSCEPTIBILITY
  association: Immune-regulatory susceptibility locus and NF-kappaB negative regulator (A20) linked to ocular autoimmunity
  notes: >-
    Encodes A20, a negative regulator of NF-kappaB signaling; reduced A20
    function disinhibits NF-kappaB activation and lowers the threshold for
    intraocular autoimmune inflammation.
  evidence:
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Additional immune-regulatory loci-STAT4, CCR1, IRF8, TNFAIP3 (A20)-have been linked in cohort- and disease-specific analyses. A20 haploinsufficiency, which normally acts as a brake on the NF-κB inflammation pathway, disinhibits NF-κB signalling, lowering activation thresholds for ocular autoimmunity (221, 224)."
    explanation: >-
      Review describing TNFAIP3 (A20) as an immune-regulatory locus whose loss of
      function disinhibits NF-kappaB signaling and promotes ocular autoimmunity.
differential_diagnoses:
- name: Intraocular lymphoma
  disease_term:
    preferred_term: intraocular lymphoma
    term:
      id: MONDO:0004351
      label: intraocular lymphoma
  description: >-
    Neoplastic uveitic masquerade syndrome (most commonly primary vitreoretinal
    lymphoma) that presents with vitreous cellular infiltration and chorioretinal
    lesions mimicking chronic intermediate, posterior, or panuveitis.
  distinguishing_features:
  - Neoplastic lymphoid infiltration rather than primary immune or infectious inflammation
  - Poor or transient response to corticosteroid monotherapy and requirement for diagnostic vitreous biopsy or cytology
  evidence:
  - reference: PMID:41877771
    reference_title: "The Immunopathogenesis of uveitis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Masquerade syndromes, accounting for 1 to 5% of presentations, comprise neoplastic processes and non-neoplastic entities such as ocular ischaemia."
    explanation: >-
      Review identifying neoplastic masquerade syndromes as an important
      differential diagnostic category in patients presenting with uveitis.
- name: Posterior uveitis
  disease_term:
    preferred_term: posterior uveitis
  description: >-
    Anatomic class of uveitis in which primary intraocular inflammation is
    restricted to the retina and/or choroid without predominant simultaneous
    involvement of the anterior chamber and vitreous cavity.
  distinguishing_features:
  - Primary inflammation confined to the choroid and/or retina (17%-23% of uveitis cases) rather than involving all uveal layers simultaneously
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
    explanation: >-
      Review distinguishing posterior uveitis (confined to choroid and/or retina)
      from panuveitis (involving all uveal layers).
- name: Anterior uveitis
  disease_term:
    preferred_term: anterior uveitis
  description: >-
    Anatomic class of uveitis limited to the anterior segment (iris and ciliary
    body), representing the most common form of uveitis (41%-60% of cases).
  distinguishing_features:
  - Inflammation restricted to the iris and ciliary body without chorioretinal or diffuse vitreous involvement
  evidence:
  - reference: PMID:40434762
    reference_title: "Uveitis in Adults: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
    explanation: >-
      Review distinguishing anterior uveitis (iris and ciliary body) from
      panuveitis (all uveal layers).
references:
- reference: PMID:40434762
  title: "Uveitis in Adults: A Review."
  findings:
  - statement: Panuveitis is an anatomic form of uveitis involving all uveal layers and accounting for 7% to 32% of adult uveitis cases, with uveitis overall predominantly affecting adults aged 20 to 50 years.
    supporting_text: "Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
  - statement: Uncontrolled uveitis across ocular compartments leads to sight-threatening structural complications including cataract, glaucoma, macular edema, retinal detachment, and optic nerve damage.
    supporting_text: "Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
- reference: PMID:41877771
  title: "The Immunopathogenesis of uveitis."
  findings:
  - statement: Uveitis has an annual incidence of 17 to 52 per 100,000 people and arises from the interaction of genetic susceptibility loci (including HLA alleles, IL23R, and TNFAIP3) with infectious or environmental triggers that breach ocular immune privilege.
    supporting_text: "The annual incidence ranges from 17 to 52 per 100,000 people, with the condition predominantly affecting young and middle-aged adults aged 20 to 50 years (3)."
- reference: PMID:37428299
  title: "The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification."
  findings:
  - statement: In the Hellenic Study of Uveitis cohort, among eyes with panuveitis, 87.1% were noninfectious and 12.9% were caused by infectious agents.
    supporting_text: "Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
- reference: PMID:39157460
  title: "Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond."
  findings:
  - statement: Pro-inflammatory cytokines TNF-alpha and IL-6 are elevated in intraocular fluids during active uveitis and serve as key therapeutic targets for biologic immunosuppression.
    supporting_text: "The pro-inflammatory cytokine TNF-α is believed to be a pivotal factor in uveitis inflammation, with upregulated levels in both aqueous humor and serum among uveitis patients."
- reference: PMID:27602665
  title: "Adalimumab in Patients with Active Noninfectious Uveitis."
  findings:
  - statement: In the phase 3 VISUAL I trial of active noninfectious intermediate, posterior, or panuveitis, adalimumab prolonged median time to treatment failure to 24 weeks compared with 13 weeks for placebo.
    supporting_text: "The median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group."
📚

References & Deep Research

References

5
PMID:40434762
Uveitis in Adults: A Review.
2 findings
Panuveitis is an anatomic form of uveitis involving all uveal layers and accounting for 7% to 32% of adult uveitis cases, with uveitis overall predominantly affecting adults aged 20 to 50 years.
"Anterior uveitis affects the iris and ciliary body (41%-60% of cases); intermediate uveitis affects the pars plana (attachment point of vitreous humor) and peripheral retina (9%-15%); posterior uveitis involves the choroid and/or retina (17%-23%); and panuveitis involves all uveal layers (7%-32%)."
Uncontrolled uveitis across ocular compartments leads to sight-threatening structural complications including cataract, glaucoma, macular edema, retinal detachment, and optic nerve damage.
"Untreated uveitis may cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and vision loss."
PMID:41877771
The Immunopathogenesis of uveitis.
1 finding
Uveitis has an annual incidence of 17 to 52 per 100,000 people and arises from the interaction of genetic susceptibility loci (including HLA alleles, IL23R, and TNFAIP3) with infectious or environmental triggers that breach ocular immune privilege.
"The annual incidence ranges from 17 to 52 per 100,000 people, with the condition predominantly affecting young and middle-aged adults aged 20 to 50 years (3)."
PMID:37428299
The large Hellenic Study of Uveitis: epidemiology, etiologic factors and classification.
1 finding
In the Hellenic Study of Uveitis cohort, among eyes with panuveitis, 87.1% were noninfectious and 12.9% were caused by infectious agents.
"Finally, for eyes with panuveitis, 12.9% were caused by infectious agents, while 87.1% were non-infectious uveitis."
PMID:39157460
Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.
1 finding
Pro-inflammatory cytokines TNF-alpha and IL-6 are elevated in intraocular fluids during active uveitis and serve as key therapeutic targets for biologic immunosuppression.
"The pro-inflammatory cytokine TNF-α is believed to be a pivotal factor in uveitis inflammation, with upregulated levels in both aqueous humor and serum among uveitis patients."
PMID:27602665
Adalimumab in Patients with Active Noninfectious Uveitis.
1 finding
In the phase 3 VISUAL I trial of active noninfectious intermediate, posterior, or panuveitis, adalimumab prolonged median time to treatment failure to 24 weeks compared with 13 weeks for placebo.
"The median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group."

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 41 citations 2026-05-09T11:28:06.348030

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Panuveitis
  • MONDO ID: (if available)
  • Category: Immune

Research Objectives

Please provide a comprehensive research report on Panuveitis covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Panuveitis (Immune category)

Executive summary

Panuveitis is an anatomic classification of uveitis in which intraocular inflammation involves all uveal regions (anterior, intermediate, and posterior) and is clinically important because it is disproportionately associated with sight-threatening complications and frequently requires systemic and/or intraocular corticosteroids plus steroid-sparing immunomodulatory therapy, with biologics (notably adalimumab) supported by high-quality randomized trials in noninfectious intermediate/posterior/panuveitis. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7, jaffe2016adalimumabinpatients pages 1-2)

A structured summary table of identifiers/epidemiology/etiologies/complications and key trial statistics is provided here:

Domain Key facts for panuveitis KB entry Source / year / DOI-URL Support
Definition / classification Panuveitis is the SUN anatomic class with inflammation involving all uveal areas (“all areas”); clinically, symptoms/signs may arise from anterior, intermediate, and posterior segments. SUN overview: Clinical & Experimental Ophthalmology (2022), DOI: 10.1111/ceo.14175, https://doi.org/10.1111/ceo.14175; JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (jabs2022thestandardisationof pages 1-3, maghsoudlou2025uveitisinadults pages 4-7)
Epidemiology In US/Europe series, panuveitis accounts for ~7–32% of uveitis. General uveitis epidemiology: prevalence ~38–714/100,000 and incidence ~17–52/100,000/year; uveitis most often affects adults 20–50 years. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 14-16)
Laterality / course Panuveitis is often bilateral (~75%) and may be more chronic than anterior/posterior forms in some cohorts; disease progression can be variable/relapsing. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358; Life (2025), DOI: 10.3390/life15060882, https://doi.org/10.3390/life15060882 (maghsoudlou2025uveitisinadults pages 4-7)
Common etiologies: infectious Important infectious causes include toxoplasmosis, herpes viruses, tuberculosis, syphilis, HIV-related infections; infectious uveitis comprises ~11–21% of cases in high-income countries and up to ~50% in low-/middle-income countries. In one summary, toxoplasmosis contributed ~1–8% among panuveitis associations. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358; Eye overview (2024), DOI: 10.1038/s41433-024-02966-w, https://doi.org/10.1038/s41433-024-02966-w (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7)
Common etiologies: noninfectious / immune Frequent noninfectious associations include sarcoidosis, Behçet disease, Vogt–Koyanagi–Harada disease and other immune-mediated/systemic disorders; 37–49% of uveitis cases are associated with systemic disease overall. Sarcoidosis was cited in ~5–29% of panuveitis associations in reviewed series. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7, chauhan2024updateonnoninfectious pages 2-4)
Key complications Panuveitis carries high risk of sight-threatening complications including macular edema, retinal detachment, cataract, glaucoma, optic nerve damage, and vision loss. Frequency ranges reported for uveitis complications include cataract 18–49%, glaucoma 7–56%, and macular edema 8–10%. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358; intravitreal therapy review (2016), DOI: 10.2147/OPTH.S89341, https://doi.org/10.2147/OPTH.S89341 (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 11-14)
Initial treatment algorithm Rule out infection first. Infectious panuveitis requires organism-directed antimicrobials; noninfectious moderate/severe intermediate/posterior/panuveitis generally needs systemic and/or intravitreal corticosteroids, with early steroid-sparing immunosuppression when chronic, bilateral, recurrent, or vision-threatening. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358; Frontiers in Ophthalmology (2024), DOI: 10.3389/fopht.2024.1412930, https://doi.org/10.3389/fopht.2024.1412930 (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 14-16, chauhan2024updateonnoninfectious pages 2-4, chauhan2024updateonnoninfectious pages 1-2)
Corticosteroids / local therapy Local steroid options used for posterior/panuveitic disease include sub-Tenon triamcinolone (1–2 months), intravitreal dexamethasone implant (3–6 months), and fluocinolone implant (~36 months). Ocular hypertension is an important toxicity: cumulative incidence at 24 weeks reported as 41% with dexamethasone implant, 30% with intravitreal triamcinolone, 20% with periocular triamcinolone. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 7-9)
DMARD evidence Conventional steroid-sparing agents remain key: methotrexate achieved remission/control in about 52.1% (95% CI 38.6–67.1%) and mycophenolate mofetil in about 70.9% (95% CI 57.1–83.5%) in summarized posterior/nonanterior uveitis data; cyclosporine and azathioprine are additional options in selected etiologies (e.g., Behçet). JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 7-9)
Biologic therapy positioning Adalimumab is the best-supported biologic and is approved for noninfectious intermediate, posterior, and panuveitis; typically used after inadequate response/intolerance to corticosteroids and/or conventional IMT, or when steroid-sparing control is needed. Frontiers in Ophthalmology (2024), DOI: 10.3389/fopht.2024.1412930, https://doi.org/10.3389/fopht.2024.1412930; NEJM (2016), DOI: 10.1056/NEJMoa1509852, https://doi.org/10.1056/NEJMoa1509852 (chauhan2024updateonnoninfectious pages 2-4, jaffe2016adalimumabinpatients pages 1-2)
RCT: adalimumab VISUAL I (active disease) VISUAL I: phase 3 RCT in active noninfectious intermediate/posterior/panuveitis. Adalimumab prolonged median time to treatment failure to 24 vs 13 weeks for placebo; HR 0.50 (95% CI 0.36–0.70), P<0.001. NEJM (2016), DOI: 10.1056/NEJMoa1509852, https://doi.org/10.1056/NEJMoa1509852 (jaffe2016adalimumabinpatients pages 1-2, jaffe2016adalimumabinpatients pages 2-3)
RCT: adalimumab VISUAL II (inactive steroid-dependent disease) VISUAL II: phase 3 RCT in inactive steroid-dependent intermediate/posterior/panuveitis. Adalimumab reduced risk of treatment failure vs placebo: HR 0.57 (95% CI 0.39–0.84), P=0.004; 40th percentile time to failure 10.2 vs 4.8 months. VISUAL II report (2016), multicentre double-masked trial; URL/DOI not fully captured in excerpt (nguyen2016adalimumabforpreventiona pages 1-6, nguyen2016adalimumabforprevention pages 6-10)
Long-term biologic data In VISUAL III long-term follow-up/open-label data summarized in review literature, quiescence increased from 34% to 85% over 3 years among noninfectious intermediate/posterior/panuveitis patients treated with adalimumab. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 11-14)
RCT: local steroid comparison In a 192-patient trial, intravitreal steroid implants reduced macular thickness at 8 weeks more than periocular triamcinolone: 39% (triamcinolone implant) and 46% (dexamethasone implant) vs 23% (periocular), p<0.0001. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 7-9)
RCT: suprachoroidal triamcinolone In a 160-patient RCT, suprachoroidal triamcinolone produced ≥15-letter visual acuity gains in 47% vs 16% with placebo at 4 weeks (p<0.001) in noninfectious uveitic macular edema/posterior segment disease contexts relevant to panuveitis care. JAMA review (2025), DOI: 10.1001/jama.2025.4358, https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 7-9)

Table: This table summarizes core disease-knowledge-base facts for panuveitis, including definition, epidemiology, etiologies, complications, and treatment evidence. It highlights the most actionable quantitative findings, especially major randomized trial results relevant to current management.

1. Disease information

1.1 What is panuveitis?

Panuveitis is a SUN (Standardization of Uveitis Nomenclature) anatomic class of uveitis describing inflammation that affects all uveal areas (“all areas”). (maghsoudlou2025uveitisinadults pages 4-7)

1.2 Key identifiers (ICD/MeSH/MONDO)

  • ICD-10 / ICD-11: Not fully retrievable from the provided evidence snippets; some literature notes alignment of reimbursement codes with ICD-10 uveitis categories (but does not explicitly provide the panuveitis ICD code in extracted text). (jabs2022thestandardisationof pages 3-4)
  • MeSH: Not retrievable from the provided evidence snippets.
  • MONDO ID: Not retrievable from the provided evidence snippets.

Because the tool-retrieved corpus did not include ontology registry pages (e.g., MONDO, MeSH browser), the KB identifiers above should be validated against those databases directly.

1.3 Synonyms / alternative names

Panuveitis is often discussed as “pan-uveitis” or “uveitis involving all anatomic locations.” (maghsoudlou2025uveitisinadults pages 4-7)

1.4 Evidence source type

The information below is derived from aggregated disease-level resources (systematic/narrative reviews, consensus/standardization efforts, randomized trials) and selected cohort studies, rather than individual EHR-derived phenotyping. (maghsoudlou2025uveitisinadults pages 1-4, jabs2022thestandardisationof pages 1-3, jaffe2016adalimumabinpatients pages 1-2)

2. Etiology

2.1 Disease causal factors (high-level)

Panuveitis is not a single etiologic disease; it is an anatomic phenotype that can arise from infectious or noninfectious (immune-mediated/systemic) conditions. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 14-16)

2.2 Risk factors and associated conditions

Infectious causes (examples)

Across settings, major infectious contributors to uveitis include toxoplasmosis, herpes viruses, tuberculosis, HIV, and syphilis; in high-income countries infectious causes contribute roughly 11–21% of uveitis, while in low-/middle-income countries they may contribute up to ~50%. (maghsoudlou2025uveitisinadults pages 1-4)

In reviewed series summarized in a 2025 JAMA uveitis review, panuveitis associations included toxoplasmosis (reported ~1–8%). (maghsoudlou2025uveitisinadults pages 4-7)

Noninfectious / immune-mediated associations (examples)

Noninfectious associations discussed in recent synthesis include sarcoidosis, Behçet disease, and Vogt–Koyanagi–Harada (VKH), among other systemic inflammatory diseases; overall, 37–49% of uveitis cases are associated with systemic disease in US/Europe series. (maghsoudlou2025uveitisinadults pages 1-4)

In the same synthesis, panuveitis associations included sarcoidosis (~5–29%) across reviewed cohorts. (maghsoudlou2025uveitisinadults pages 4-7)

2.3 Protective factors

No protective factors specific to panuveitis were identified in the retrieved evidence corpus.

2.4 Gene–environment interactions

The retrieved evidence notes that uveitis epidemiology is influenced by genetic factors (e.g., HLA associations) and environmental factors (e.g., air pollution), but gene–environment interaction effects specific to panuveitis were not extractable from the provided excerpts. (maghsoudlou2025uveitisinadults pages 1-4)

3. Phenotypes (clinical features)

3.1 Common symptom/sign phenotypes

Panuveitis produces combined manifestations from the three uveal regions; uveitis generally presents with eye redness, pain, photophobia, floaters, and blurred vision. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7)

3.2 Sight-threatening features/complications as phenotypes

Panuveitis (grouped with moderate–severe intermediate and posterior uveitis) is highlighted as high risk for sight-threatening complications, including macular edema and severe posterior segment inflammation. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 7-9)

3.3 Quality-of-life impact

Direct quantitative QoL statistics for panuveitis were not present in the retrieved evidence. However, the clinical emphasis that uveitis is a major cause of irreversible vision loss implies substantial functional impact when complications occur. (chauhan2024updateonnoninfectious pages 1-2, maghsoudlou2025uveitisinadults pages 1-4)

3.4 Suggested HPO terms (non-exhaustive; ontology suggestions)

  • Eye pain: HP:0030038
  • Photophobia: HP:0000613
  • Floaters: HP:0030319
  • Blurred vision: HP:0000622
  • Cystoid macular edema: HP:0001103
  • Cataract: HP:0000518
  • Glaucoma: HP:0000501
  • Retinal detachment: HP:0000541

(These are ontology suggestions; confirmation against HPO is recommended.)

4. Genetic / molecular information

4.1 Causal genes and pathogenic variants

Panuveitis is an anatomic descriptor rather than a monogenic disorder; causal genes/variants are typically defined at the level of underlying specific uveitic diseases (e.g., systemic inflammatory syndromes), not the panuveitis anatomic class. No gene-specific variant claims were retrievable from the evidence corpus provided.

4.2 Immune mechanisms and pathways (current understanding)

A recent synthesis describes uveitis as involving loss of ocular immune privilege and inflammatory pathways including Th1/Th17 and cytokines including IL-6 and TNF-α—a mechanistic rationale consistent with the clinical efficacy of anti-TNF biologics in noninfectious intermediate/posterior/panuveitis. (maghsoudlou2025uveitisinadults pages 14-16, chauhan2024updateonnoninfectious pages 2-4)

4.3 Suggested GO / CL ontology terms (mechanism/cell-type suggestions)

  • GO: inflammatory response (GO:0006954)
  • GO: regulation of T cell activation (GO:0050863)
  • GO: cytokine-mediated signaling pathway (GO:0019221)
  • Cell types: T helper 17 cell (CL:0000899), CD4-positive T cell (CL:0000624), macrophage (CL:0000235)

(These are ontology suggestions; confirmation against GO/CL is recommended.)

5. Environmental information

No panuveitis-specific environmental toxin or lifestyle risk-factor statistics were retrievable from the provided evidence. Uveitis incidence/prevalence is described as influenced by environmental factors such as air pollution at a general level. (maghsoudlou2025uveitisinadults pages 1-4)

6. Mechanism / pathophysiology

6.1 Causal chain (conceptual)

  1. Trigger/underlying disease: infection (e.g., toxoplasmosis, herpes viruses, TB, syphilis) or immune-mediated systemic disease (e.g., sarcoidosis, Behçet, VKH). (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7)
  2. Immune activation in ocular tissues: breakdown of immune privilege and inflammatory cytokine signaling (e.g., TNF-α, IL-6; Th1/Th17-related responses). (maghsoudlou2025uveitisinadults pages 14-16, chauhan2024updateonnoninfectious pages 2-4)
  3. Tissue injury: inflammation of iris/ciliary body/choroid with spillover to vitreous/retina and downstream complications such as macular edema, glaucoma/cataract, retinal detachment, optic nerve damage. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 7-9)
  4. Clinical outcomes: reduced visual acuity and potential irreversible vision loss if uncontrolled. (maghsoudlou2025uveitisinadults pages 1-4)

7. Anatomical structures affected

7.1 Organ level

Primary organ: eye (uveal tract and adjacent intraocular structures). (maghsoudlou2025uveitisinadults pages 1-4)

7.2 Tissue / intraocular compartments

The anatomic distribution explicitly includes iris/ciliary body/choroid (uvea), and clinical consequences include involvement of retina/macula and optic nerve structures via macular edema, retinal detachment, and optic nerve damage. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 7-9)

7.3 Suggested UBERON terms (examples; ontology suggestions)

  • Eye: UBERON:0000970
  • Uvea: UBERON:0001777
  • Retina: UBERON:0000966
  • Choroid: UBERON:0001775

8. Temporal development (onset, course)

Uveitis most commonly affects adults aged ~20–50 years. Panuveitis may be bilateral (~75%) and is managed as higher-risk disease often needing systemic therapy, consistent with potential chronic/relapsing courses in noninfectious disease. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7)

9. Inheritance and population

9.1 Epidemiology (recently summarized ranges)

A 2025 clinical synthesis reports broad ranges for uveitis epidemiology: prevalence ~38–714 per 100,000 and incidence ~17–52 per 100,000/year; within uveitis cohorts, panuveitis represented ~7–32% of cases (US/Europe) and could be higher in some regions. (maghsoudlou2025uveitisinadults pages 14-16, maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 4-7)

9.2 Population demographics

The same synthesis notes uveitis is most frequent in working-age adults (~20–50) with a slight female predominance (uveitis overall), but panuveitis-specific sex ratios were not extractable from the provided text. (maghsoudlou2025uveitisinadults pages 14-16)

10. Diagnostics

10.1 Workup principles

Because panuveitis spans infectious and immune causes, evaluation emphasizes testing for infection (e.g., syphilis) and systemic disease (e.g., sarcoidosis), with ocular sampling when infection is suspected. (maghsoudlou2025uveitisinadults pages 4-7, maghsoudlou2025uveitisinadults pages 14-16)

10.2 Imaging: current applications and real-world implementation (2023–2024 emphasis)

Fundus autofluorescence (FAF)

A 2024 review emphasizes FAF as a prompt, non-invasive modality helpful in detecting and monitoring retinal/choroidal abnormalities in posterior uveitis and panuveitis; FAF is described as useful for staging, mapping lesion extent beyond clinical exam, and monitoring activity/response, with disease- and stage-dependent patterns (often hyperautofluorescence in active inflammation, hypoautofluorescence in atrophy/inactive disease, with important entity-specific exceptions). (mauschitz2024fundusautofluorescencein pages 2-4, mauschitz2024fundusautofluorescencein pages 15-16, mauschitz2024fundusautofluorescencein pages 13-15)

Practical limitations include that FAF alone cannot reliably subtype uveitis, may be impacted by media opacity, and should be used as part of multimodal imaging with OCT/angiography and clinical/laboratory correlation. (mauschitz2024fundusautofluorescencein pages 15-16)

Artificial intelligence for diagnosis/classification

A major SUN standardization effort incorporated machine learning to derive classification criteria for 25 common uveitic diseases from a curated retrospective dataset, reporting high validation performance across anatomic classes. In validation, reported accuracy by anatomic class included panuveitides ~94.0% and infectious posterior/panuveitides ~93.3%; performance on a masked-observer application of final rules was reported as panuveitides ~98.9% and infectious posterior/panuveitides ~98.8%. (jabs2022thestandardisationof pages 6-7)

Key caveats described for the SUN approach include lack of a diagnostic gold standard, moderate expert agreement historically, and incomplete retrospective data requiring an “evidence for” approach to missingness; additionally, the project used graded image results rather than raw images for machine learning. (jabs2022thestandardisationof pages 3-4, jabs2022thestandardisationof pages 4-6)

10.3 Molecular diagnostics for infectious panuveitis (metagenomic sequencing)

A 2025 clinical study using intraocular-fluid metagenomic next-generation sequencing (mNGS) in suspected infectious uveitis reported mNGS positivity 73.97% vs culture 3.45%, supporting mNGS as a high-yield tool when infection is in the differential. In this cohort, all patients were described as presenting with panuveitis, and 14 cases were complicated by retinal detachment. (shen2025virusininfectious pages 1-2, shen2025virusininfectious pages 4-5)

11. Outcome / prognosis

Untreated uveitis can result in vision-threatening structural complications including cataract, glaucoma, macular edema, retinal detachment, and optic nerve damage. (maghsoudlou2025uveitisinadults pages 1-4)

In a recent synthesis, reported frequency ranges for uveitis complications included cataract 18–49%, glaucoma 7–56%, and macular edema 8–10%. (maghsoudlou2025uveitisinadults pages 11-14)

12. Treatment

12.1 Treatment goals

The overarching goal is to induce and maintain remission while minimizing corticosteroid toxicity, with etiologic therapy (antimicrobial) prioritized for infectious disease. (maghsoudlou2025uveitisinadults pages 1-4)

12.2 Pharmacotherapy and immunomodulatory therapy (current practice)

Patients with moderate–severe intermediate uveitis, posterior uveitis, and panuveitis are emphasized as higher risk for sight-threatening outcomes and generally require systemic and/or intravitreal corticosteroids and steroid-sparing immunosuppressive agents. (maghsoudlou2025uveitisinadults pages 1-4, maghsoudlou2025uveitisinadults pages 7-9)

Corticosteroids (systemic/local)

Local steroid delivery options and typical durations include sub-Tenon triamcinolone (1–2 months), intravitreal dexamethasone implant (3–6 months), and fluocinolone implant (~36 months); ocular hypertension risk varies by delivery method (e.g., cumulative ocular hypertension at 24 weeks: dexamethasone implant 41%, intravitreal triamcinolone 30%, periocular 20%). (maghsoudlou2025uveitisinadults pages 7-9)

Conventional steroid-sparing IMT (DMARDs)

In summarized posterior/nonanterior uveitis data, methotrexate achieved remission/control in 52.1% (95% CI 38.6–67.1) and mycophenolate mofetil achieved control in 70.9% (95% CI 57.1–83.5). (maghsoudlou2025uveitisinadults pages 1-4)

Biologics (2023–2024 context and evidence base)

A 2024 review emphasizes that biologics are used for corticosteroid-intolerant/resistant disease, highlighting TNF-α inhibitors, and notes that adalimumab is approved for noninfectious intermediate, posterior, and panuveitis. (chauhan2024updateonnoninfectious pages 2-4)

Adalimumab – randomized trial evidence (VISUAL program)
  • VISUAL I (active disease) (NEJM, Sep 2016; DOI: 10.1056/NEJMoa1509852; URL: https://doi.org/10.1056/NEJMoa1509852): In active noninfectious intermediate/posterior/panuveitis, adalimumab prolonged median time to treatment failure to 24 weeks vs 13 weeks with placebo (HR 0.50, 95% CI 0.36–0.70; P<0.001). (jaffe2016adalimumabinpatients pages 1-2)
  • Abstract quote (from extracted excerpt): “median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.” (jaffe2016adalimumabinpatients pages 1-2)
  • VISUAL II (inactive, steroid-dependent disease): In inactive steroid-dependent intermediate/posterior/panuveitis, adalimumab reduced treatment failure risk (HR 0.57, 95% CI 0.39–0.84; P=0.004) with a reported 40th percentile time to treatment failure 10.2 vs 4.8 months (adalimumab vs placebo). (nguyen2016adalimumabforpreventiona pages 1-6)

Longer-term follow-up summarized in a 2025 clinical synthesis notes VISUAL III data with quiescence increasing from 34% to 85% over 3 years on adalimumab in noninfectious intermediate/posterior/panuveitis. (maghsoudlou2025uveitisinadults pages 11-14)

12.3 Real-world implementations

Implementation patterns emphasized in recent syntheses include (i) multidisciplinary care when systemic inflammatory disease is present and (ii) escalation from corticosteroids to immunosuppressants and then biologics for refractory disease. (maghsoudlou2025uveitisinadults pages 1-4, chauhan2024updateonnoninfectious pages 2-4)

12.4 Treatment outcomes: local steroid trials relevant to posterior-segment inflammation

A 2025 synthesis reports trials supporting local corticosteroid approaches relevant to posterior-segment inflammation seen in panuveitis: * In a 192-patient trial, intravitreal steroid implants reduced macular thickness at 8 weeks more than periocular triamcinolone (39% and 46% vs 23%; p<0.0001). (maghsoudlou2025uveitisinadults pages 7-9) * In a 160-patient RCT, suprachoroidal triamcinolone produced ≥15-letter VA gains in 47% vs 16% with placebo at 4 weeks (p<0.001). (maghsoudlou2025uveitisinadults pages 7-9)

12.5 MAXO term suggestions (treatment actions; ontology suggestions)

  • Corticosteroid therapy (systemic and local ocular delivery)
  • Immunosuppressive therapy (e.g., antimetabolite therapy)
  • Anti-TNF therapy (adalimumab)
  • Intravitreal drug delivery / ocular implant therapy

13. Prevention

No panuveitis-specific primary-prevention interventions were identified in the retrieved corpus. Preventive strategy is largely secondary/tertiary: early identification of infectious etiologies (to avoid inappropriate immunosuppression) and early initiation of steroid-sparing control to prevent recurrent inflammatory damage. (maghsoudlou2025uveitisinadults pages 14-16, maghsoudlou2025uveitisinadults pages 1-4)

14. Other species / natural disease

No veterinary/natural panuveitis evidence in other species was retrieved within the provided corpus.

15. Model organisms

No model-organism evidence was retrieved within the provided corpus. (Note: uveitis research commonly uses experimental autoimmune uveitis models, but this claim cannot be supported from the current evidence set.)

Recent developments (prioritizing 2023–2024)

  • Imaging/monitoring: 2024 review highlights expanding and entity-specific use of fundus autofluorescence (including ultra-widefield and multi-wavelength FAF) for diagnosis, staging, and monitoring posterior uveitis/panuveitis, emphasizing multimodal imaging integration. Publication date: Apr 2024; URL: https://doi.org/10.3390/biom14050515. (mauschitz2024fundusautofluorescencein pages 2-4, mauschitz2024fundusautofluorescencein pages 15-16)
  • Therapeutic landscape: 2024 review synthesizes “anti-TNF-alpha and beyond” strategies for noninfectious uveitis, positioning biologics as key steroid-sparing options when conventional therapy fails; publication date: Aug 2024; URL: https://doi.org/10.3389/fopht.2024.1412930. (chauhan2024updateonnoninfectious pages 2-4)
  • AI/classification infrastructure: SUN project report (Oct 2022) documents the machine-learning-based development of classification criteria for common uveitides with high reported accuracy in panuveitides and infectious posterior/panuveitides categories, illustrating a pathway toward more standardized research cohorts. Publication date: Oct 2022; URL: https://doi.org/10.1111/ceo.14175. (jabs2022thestandardisationof pages 6-7, jabs2022thestandardisationof pages 4-6)

Limitations of this report (evidence availability)

  1. PMIDs: Although multiple primary trials were retrieved with DOIs and journal information, PMIDs were not present in the extracted text snippets, so PMID-level citation could not be reliably provided without external lookup. (jaffe2016adalimumabinpatients pages 1-2, nguyen2016adalimumabforpreventiona pages 1-6)
  2. Ontology IDs (MONDO/MeSH/ICD): MONDO/MeSH/ICD identifiers for panuveitis were not present in the retrieved excerpts; this report therefore flags them as not retrievable from the current tool evidence. (jabs2022thestandardisationof pages 3-4)
  3. Genetics/model organisms: The current corpus did not contain panuveitis-specific genetic variant evidence or model organism summaries.

Key references with URLs and publication dates

  • Maghsoudlou P, et al. Uveitis in Adults: A Review. JAMA. May 2025. https://doi.org/10.1001/jama.2025.4358 (maghsoudlou2025uveitisinadults pages 1-4)
  • Jaffe GJ, et al. Adalimumab in Patients with Active Noninfectious Uveitis (VISUAL I). N Engl J Med. Sep 2016. https://doi.org/10.1056/NEJMoa1509852 (jaffe2016adalimumabinpatients pages 1-2)
  • Chauhan K, Tyagi M. Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. Frontiers in Ophthalmology. Aug 2024. https://doi.org/10.3389/fopht.2024.1412930 (chauhan2024updateonnoninfectious pages 2-4)
  • Mauschitz MM, et al. Fundus Autofluorescence in Posterior and Panuveitis—An Under-Estimated Imaging Technique. Biomolecules. Apr 2024. https://doi.org/10.3390/biom14050515 (mauschitz2024fundusautofluorescencein pages 2-4)
  • Jabs DA, et al. The standardisation of uveitis nomenclature (SUN) project. Clin Exp Ophthalmol. Oct 2022. https://doi.org/10.1111/ceo.14175 (jabs2022thestandardisationof pages 1-3)
  • Shen J, et al. Virus in infectious uveitis: bibliometric analysis and a clinical study (mNGS yield). Frontiers in Microbiology. Aug 2025. https://doi.org/10.3389/fmicb.2025.1588195 (shen2025virusininfectious pages 1-2)

References

  1. (maghsoudlou2025uveitisinadults pages 1-4): Panayiotis Maghsoudlou, Simon J. Epps, Catherine M. Guly, and Andrew D. Dick. Uveitis in adults: a review. JAMA, May 2025. URL: https://doi.org/10.1001/jama.2025.4358, doi:10.1001/jama.2025.4358. This article has 47 citations.

  2. (maghsoudlou2025uveitisinadults pages 4-7): Panayiotis Maghsoudlou, Simon J. Epps, Catherine M. Guly, and Andrew D. Dick. Uveitis in adults: a review. JAMA, May 2025. URL: https://doi.org/10.1001/jama.2025.4358, doi:10.1001/jama.2025.4358. This article has 47 citations.

  3. (jaffe2016adalimumabinpatients pages 1-2): Glenn J. Jaffe, Andrew D. Dick, Antoine P. Brézin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine, 375:932-943, Sep 2016. URL: https://doi.org/10.1056/nejmoa1509852, doi:10.1056/nejmoa1509852. This article has 746 citations and is from a highest quality peer-reviewed journal.

  4. (jabs2022thestandardisationof pages 1-3): Douglas A. Jabs, Peter McCluskey, Alan G. Palestine, Jennifer E. Thorne, and The Standardization of Uveitis Nomenclature (SUN) Working Gr. The standardisation of uveitis nomenclature (sun) project. Clinical & Experimental Ophthalmology, 50:991-1000, Oct 2022. URL: https://doi.org/10.1111/ceo.14175, doi:10.1111/ceo.14175. This article has 45 citations and is from a peer-reviewed journal.

  5. (maghsoudlou2025uveitisinadults pages 14-16): Panayiotis Maghsoudlou, Simon J. Epps, Catherine M. Guly, and Andrew D. Dick. Uveitis in adults: a review. JAMA, May 2025. URL: https://doi.org/10.1001/jama.2025.4358, doi:10.1001/jama.2025.4358. This article has 47 citations.

  6. (chauhan2024updateonnoninfectious pages 2-4): Khushboo Chauhan and Mudit Tyagi. Update on non-infectious uveitis treatment: anti-tnf-alpha and beyond. Frontiers in Ophthalmology, Aug 2024. URL: https://doi.org/10.3389/fopht.2024.1412930, doi:10.3389/fopht.2024.1412930. This article has 15 citations.

  7. (maghsoudlou2025uveitisinadults pages 11-14): Panayiotis Maghsoudlou, Simon J. Epps, Catherine M. Guly, and Andrew D. Dick. Uveitis in adults: a review. JAMA, May 2025. URL: https://doi.org/10.1001/jama.2025.4358, doi:10.1001/jama.2025.4358. This article has 47 citations.

  8. (chauhan2024updateonnoninfectious pages 1-2): Khushboo Chauhan and Mudit Tyagi. Update on non-infectious uveitis treatment: anti-tnf-alpha and beyond. Frontiers in Ophthalmology, Aug 2024. URL: https://doi.org/10.3389/fopht.2024.1412930, doi:10.3389/fopht.2024.1412930. This article has 15 citations.

  9. (maghsoudlou2025uveitisinadults pages 7-9): Panayiotis Maghsoudlou, Simon J. Epps, Catherine M. Guly, and Andrew D. Dick. Uveitis in adults: a review. JAMA, May 2025. URL: https://doi.org/10.1001/jama.2025.4358, doi:10.1001/jama.2025.4358. This article has 47 citations.

  10. (jaffe2016adalimumabinpatients pages 2-3): Glenn J. Jaffe, Andrew D. Dick, Antoine P. Brézin, Quan Dong Nguyen, Jennifer E. Thorne, Philippe Kestelyn, Talin Barisani-Asenbauer, Pablo Franco, Arnd Heiligenhaus, David Scales, David S. Chu, Anne Camez, Nisha V. Kwatra, Alexandra P. Song, Martina Kron, Samir Tari, and Eric B. Suhler. Adalimumab in patients with active noninfectious uveitis. New England Journal of Medicine, 375:932-943, Sep 2016. URL: https://doi.org/10.1056/nejmoa1509852, doi:10.1056/nejmoa1509852. This article has 746 citations and is from a highest quality peer-reviewed journal.

  11. (nguyen2016adalimumabforpreventiona pages 1-6): QD Nguyen, PT Merrill, GJ Jaffe, AD Dick, and SK Kurup. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (visual ii): a multicentre, double-masked …. Unknown journal, 2016.

  12. (nguyen2016adalimumabforprevention pages 6-10): QD Nguyen, PT Merrill, GJ Jaffe, AD Dick, and SK Kurup. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (visual ii): a multicentre, double-masked …. Unknown journal, 2016.

  13. (jabs2022thestandardisationof pages 3-4): Douglas A. Jabs, Peter McCluskey, Alan G. Palestine, Jennifer E. Thorne, and The Standardization of Uveitis Nomenclature (SUN) Working Gr. The standardisation of uveitis nomenclature (sun) project. Clinical & Experimental Ophthalmology, 50:991-1000, Oct 2022. URL: https://doi.org/10.1111/ceo.14175, doi:10.1111/ceo.14175. This article has 45 citations and is from a peer-reviewed journal.

  14. (mauschitz2024fundusautofluorescencein pages 2-4): Matthias M. Mauschitz, Markus Zeller, Pradeep Sagar, Suchitra Biswal, Gabriela Guzman, Jan H. Terheyden, Carsten H. Meyer, Frank G. Holz, Carsten Heinz, Uwe Pleyer, Robert P. Finger, and Maximilian W. M. Wintergerst. Fundus autofluorescence in posterior and panuveitis—an under-estimated imaging technique: a review and case series. Biomolecules, 14:515, Apr 2024. URL: https://doi.org/10.3390/biom14050515, doi:10.3390/biom14050515. This article has 3 citations.

  15. (mauschitz2024fundusautofluorescencein pages 15-16): Matthias M. Mauschitz, Markus Zeller, Pradeep Sagar, Suchitra Biswal, Gabriela Guzman, Jan H. Terheyden, Carsten H. Meyer, Frank G. Holz, Carsten Heinz, Uwe Pleyer, Robert P. Finger, and Maximilian W. M. Wintergerst. Fundus autofluorescence in posterior and panuveitis—an under-estimated imaging technique: a review and case series. Biomolecules, 14:515, Apr 2024. URL: https://doi.org/10.3390/biom14050515, doi:10.3390/biom14050515. This article has 3 citations.

  16. (mauschitz2024fundusautofluorescencein pages 13-15): Matthias M. Mauschitz, Markus Zeller, Pradeep Sagar, Suchitra Biswal, Gabriela Guzman, Jan H. Terheyden, Carsten H. Meyer, Frank G. Holz, Carsten Heinz, Uwe Pleyer, Robert P. Finger, and Maximilian W. M. Wintergerst. Fundus autofluorescence in posterior and panuveitis—an under-estimated imaging technique: a review and case series. Biomolecules, 14:515, Apr 2024. URL: https://doi.org/10.3390/biom14050515, doi:10.3390/biom14050515. This article has 3 citations.

  17. (jabs2022thestandardisationof pages 6-7): Douglas A. Jabs, Peter McCluskey, Alan G. Palestine, Jennifer E. Thorne, and The Standardization of Uveitis Nomenclature (SUN) Working Gr. The standardisation of uveitis nomenclature (sun) project. Clinical & Experimental Ophthalmology, 50:991-1000, Oct 2022. URL: https://doi.org/10.1111/ceo.14175, doi:10.1111/ceo.14175. This article has 45 citations and is from a peer-reviewed journal.

  18. (jabs2022thestandardisationof pages 4-6): Douglas A. Jabs, Peter McCluskey, Alan G. Palestine, Jennifer E. Thorne, and The Standardization of Uveitis Nomenclature (SUN) Working Gr. The standardisation of uveitis nomenclature (sun) project. Clinical & Experimental Ophthalmology, 50:991-1000, Oct 2022. URL: https://doi.org/10.1111/ceo.14175, doi:10.1111/ceo.14175. This article has 45 citations and is from a peer-reviewed journal.

  19. (shen2025virusininfectious pages 1-2): Junhui Shen, Jinfeng Kong, Yufeng Xu, Yanyan Hu, and Lei Feng. Virus in infectious uveitis: bibliometric analysis and a clinical study. Frontiers in Microbiology, Aug 2025. URL: https://doi.org/10.3389/fmicb.2025.1588195, doi:10.3389/fmicb.2025.1588195. This article has 0 citations and is from a peer-reviewed journal.

  20. (shen2025virusininfectious pages 4-5): Junhui Shen, Jinfeng Kong, Yufeng Xu, Yanyan Hu, and Lei Feng. Virus in infectious uveitis: bibliometric analysis and a clinical study. Frontiers in Microbiology, Aug 2025. URL: https://doi.org/10.3389/fmicb.2025.1588195, doi:10.3389/fmicb.2025.1588195. This article has 0 citations and is from a peer-reviewed journal.